XML 59 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisitions - Narrative (Details) - USD ($)
4 Months Ended 12 Months Ended
Aug. 23, 2018
Apr. 20, 2017
Dec. 31, 2018
Dec. 31, 2018
Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]          
Contingent consideration payable     $ 310,240,000 $ 310,240,000 $ 0
Issuance of common stock related to acquisition       $ 155,860,000 75,191,000
Useful life       7 years  
Intellectual Property | Marathon Pharmaceuticals, LLC          
Finite-Lived Intangible Assets [Line Items]          
Cash consideration   $ 75,000,000      
Issuance of common stock related to acquisition (in shares)   6,683,598   6,683,598  
Issuance of common stock related to acquisition   $ 75,200,000      
Acquisition costs   $ 2,200,000      
Useful life   7 years      
Non-collaborative Arrangement Transactions | Marathon Pharmaceuticals, LLC          
Finite-Lived Intangible Assets [Line Items]          
Cash consideration   $ 75,000,000      
Equity interest issued or issuable, number of shares (in shares)   6,683,598      
Numerator for calculation of number of shares of equity interests issued to acquire entity   $ 65,000,000      
Trading day period   15 days      
Development milestone payment obligations   $ 50,000,000      
Agilis          
Finite-Lived Intangible Assets [Line Items]          
Cash consideration $ 49,221,000        
Equity interest issued or issuable, number of shares (in shares) 3,500,907        
Fair value of PTC common stock issued $ 155,860,000        
Estimated fair value of contingent consideration payable 290,500,000        
Deferred consideration payable 38,100,000        
Business combination, consideration 533,681,000        
Acquisition Related Costs       $ 1,700,000  
Net loss attributable to common stockholders       $ (138,083,000) $ (93,333,000)
Issuance of common stock related to acquisition (in shares)       3,500,907  
Numerator for calculation of number of shares of equity interests issued to acquire entity $ 150,000,000        
Trading day period 10 days        
Earnings (loss) of acquire since acquisition date     (8,700,000)    
Development milestone payment obligations $ 40,000,000   40,000,000 $ 40,000,000  
Agilis | Non-collaborative Arrangement Transactions          
Finite-Lived Intangible Assets [Line Items]          
Development milestone payment obligations $ 40,000,000   40,000,000 40,000,000  
Acquisition-related Costs | Agilis          
Finite-Lived Intangible Assets [Line Items]          
Net loss attributable to common stockholders       1,700,000  
Maximum | Agilis          
Finite-Lived Intangible Assets [Line Items]          
Priority review voucher amount       535,000,000.0  
Net sales milestones     $ 150,000,000 $ 150,000,000  
Percentage of annual net sales     600.00% 600.00%  
Development milestone payment obligations     $ 60,000,000.0 $ 60,000,000.0  
Minimum | Agilis          
Finite-Lived Intangible Assets [Line Items]          
Percentage of annual net sales     200.00% 200.00%